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OL-010 Sequential use of nitazoxanide (NTZ) as a
salvage therapy in patient with recurrent
mild to moderate Clostridium difﬁcile
infection (CDI): a prospective, open-label,
randomized clinical trial
P.P. Basu1,2 *, N.J. Shah2, N. Krishnaswamy2, R. Korapati2,
S. Tammisetti2, C.C. Tang2. 1Columbia University, New
York, 2North Shore University Hospital at Forest Hills, NY,
USA
Objectives: Vancomycin and metronidazole are currently
the recommend therapies for CDI. Treatment failure is due
to increasing antimicrobial resistance, insufﬁcient length
of therapy and suboptimal drug exposure. Recurrence is
estimated up to 20 50% in susceptible populations. We
utilize a novel sequential nitazoxanide treatment for 28
days for recurrent CDI.
Methods: Thirty (n = 30) patients (age:57.9±8.1 years; 13
non-hospital and 17 hospital acquired) were treated with
oral vancomycin or metronidazole for 14 days and had
recurrent CDI within 60 days post treatment. All patients had
abdominal pain, fever, diarrhea >3 times/day, leukocytes
>12,000, and positive stool toxin assay with Elisa A/B. All
were randomized into two groups: Group A (n = 15) patients
received nitazoxanide 500mg BID for 14 days, followed by
250mg BID for 7 days, followed by 125mg BID for 7 days;
Group B (n = 15) received vancomycin 250mg QID for 14
days, followed by 250mg BID for 7 days, followed by 125mg
BID for 7 days. Exclusion criteria: sepsis, toxic megacolon,
inﬂammatory bowel disease, Celiac disease, other colitidies,
renal sufﬁciency, probiotic use, immunocompromized state,
hemodialysis, or recent chemotherapy.
Results: Stool assay PCR for CDI was negative in 10/15
(66.7%) patients after sequential nitazoxanide treatment
and in 11/15 (73.3%) patients with sequential vancomycin
therapy. There was no signiﬁcant difference (p = 0.99,
Fisher’s exact test) in fecal eradication rate of CDI between
the two treatment groups. Side effects with nitazoxanide
treatment were minimal including nausea (n = 3), vomiting
(n = 1), constipation (n = 4), bloating (n = 2), loss of appetite
(n = 5), and yellow skin color (n = 3). This was comparable
to vancomycin.
Conclusion: This novel sequential therapy with nitazoxanide
shows a comparable cure rate to sequential oral
vancomycin treatment for recurrent CDI. Nitazoxanide has
an advantageous cost beneﬁt over oral vancomycin with
minimal side effects. A larger, double-blinded clinical trial
is warranted for validation.
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PL-003 Studies on constructing epidemic dynamic
system model and applying contact network
technique to novel inﬂuenza
S.-C. Ou1, H.-Y. Chung2, C.-Y. Chung2 *. 1Department of
Computer Science and Information Engineering, Leader
University, 2Department of Electrical Engineering, National
Central University, Taiwan
In the recent year, the Biomathematics has become the
main important trend of research direction which has
applied to the epidemic models of disease mechanism,
spreading regulation, and stategy of disease preventing in
the ﬁeld of medical and public health. Vector-borne disease
transmissions are inﬂuenced by vector population and
human population. In order to simulate the transmissions
of vector-borne diseases and discuss the related health
policies effects on vector-borne diseases, we combine the
multi-agent-based system, social network, mirror identity
concept, and compartmental model to develop an epidemic
simulation model. In the identity level, we use the
multi-agent-based system and the mirror identity concept
to describe identities with social network features such
as daily visits, long-distance movement, high degree of
clustering, low degree of separation, and local clustering.
In the vector level, we use compartment model concept
to describe the vector populations and the transmission
between populations.
The model will simulate a novel inﬂuenza outbreak and
other scenarios involving different seeding events and
interventions for example, antiviral prophylaxis, social
distancing policies or closures for schools and workplaces,
and control of inter-area movement.
The research will analyze the complex dynamic
mathematic model of novel inﬂuenza epidemic and
determine its stability property by using the popular
Matlab/Simulinksoftware and relative software packages.
Facing to the currently novel inﬂuenza epidemic situation,
in this project we will investgate the development of novel
inﬂuenza and its developing trend throught constructing the
dynamic biomathematics system model of novel inﬂuenza.
We will try to constructing epidemic dynamic system model
and applying contact network technique to novel Inﬂuenza
to ﬁnd the quarantining parameters which are the most
important factors to control epidemic situation, as shown
in the examples. The results of experiment by numerical
analysis may offer some prevention with reference to
control epidemic situation of novel inﬂuenza.
OL-011 Clinical features and 3-month follow up study of
pneumonia caused by inﬂuenza A (H1N1) virus
in Beijing, China
L. Bai1 *, L. Gu1, B. Cao1, X.-L. Zhai2, M. Lu3, L. Zhang2,
Z.-F. Gao4, K.-W. Huang5, Y.-M. Liu1, S.-F. Song1, L. Wu1,
Y.-D. Yin1, C. Wang1. 1Department of Infectious Diseases
and Clinical Microbiology, Beijing Chao-Yang Hospital,
Capital Medical University, Beijing, 2Department of
Radiology, Beijing Chao-Yang Hospital, Medical University,
3Department of Pathology, Beijng University Capital,
4Department of Pathology, Beijng University Capital,
5Department of Respiratory and Intensive Care Medicine,
Beijing Institute of Respiratory Medicine, Beijing Chao-Yang
Hospital, Capital Medical University, Beijing, China
Background: Data of symptomatic and radiographic changes
in patients with 2009 pandemic inﬂuenza A (H1N1)
pneumonia in the convalescent periods was not available.
Methods: During October 26, 2009 and January 23, 2010, 71
cases with pneumonia caused by 2009 pandemic inﬂuenza A
(H1N1) were observed during 3-month follow-up, clinical
data were collected, high-resolution chest CT and lung
function tests were performed.
Results: Of the 71 cases, median age was 41 (IQR 28
to 56) years; 63.4% were male, 54.9% had at least one
underlying medical condition. 68 patients received antiviral
treatment, and 33 received intravenous corticosteroids.
36 of 71 patients developed acute respiratory distress
syndrome during the illness. Of 25 patients who were
treated with mechanical ventilation, 14 survived with
noninvasive ventilation. 9 patients died at a median of
16 (IQR 10 to 24) days after onset of illness. Two risk
factors were identiﬁed to be independently associated with
death analyzed by multivariate Cox regression: progressing
dyspnea after resolution of fever (relative risk, 5.667;
